Figures & data
Table 1. Hexaxim composition (per 0.5 mL dose).
Figure 1. Hexaxim use in clinical practices around the world in the past decade (2013 – 2023).
![Figure 1. Hexaxim use in clinical practices around the world in the past decade (2013 – 2023).](/cms/asset/607f70f6-d9d1-4ef2-8c3d-db4c4661c6d1/ierv_a_2280236_f0001_oc.jpg)
Figure 2. Seroprotection/Seroconversion rates 1 month after a primary vaccination with 2 or 3 doses of Hexaxim.
![Figure 2. Seroprotection/Seroconversion rates 1 month after a primary vaccination with 2 or 3 doses of Hexaxim.](/cms/asset/cf9d3f39-7ff8-4459-8a19-5bb4aa8e8bf5/ierv_a_2280236_f0002_oc.jpg)
Figure 3. Seroprotection/Seroconversion rates 1 month after a booster vaccination of Hexaxim in the second year of life.
![Figure 3. Seroprotection/Seroconversion rates 1 month after a booster vaccination of Hexaxim in the second year of life.](/cms/asset/56549964-7ece-4f10-8a91-d329fa7cf7d2/ierv_a_2280236_f0003_oc.jpg)
Table 2. Summary of Hexaxim clinical trials (primary series, booster, and antibody persistence).
Figure 4. Persistent immune memory to HB following 2, 4, 6 month primary series vaccination of Hexaxim and no booster.
![Figure 4. Persistent immune memory to HB following 2, 4, 6 month primary series vaccination of Hexaxim and no booster.](/cms/asset/7dd9eef7-cdc7-4cef-a6ad-4545d94e3be7/ierv_a_2280236_f0004_oc.jpg)
Table 3. Solicited reactions after any infant vaccination – integrated analysis of Hexaxim versus Infanrix hexa.
Table 4. Characteristics of AE reports and the 10 most common events reported after DTaP-IPV-HB-Hib vaccination (June 1, 2013 to April 17, 2023).
Table 5. Observed versus expected analysis for Sudden Infant Death Syndrome/Sudden Death in the European Economic Area.